Roche's Atezolizumab Shrinks Tumors in Lung, Bladder Cancer

  • Study finds 17% to 27% of lung patients respond to treatment
  • New class of cancer drugs harnesses the immune system

Roche Holding AG, the world’s biggest maker of cancer drugs, said its experimental medicine atezolizumab shrank lung and bladder tumors in separate studies that the company plans to use to apply for U.S. regulatory approval.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.